Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection [1]

Clinical Infectious Diseases

Volumn 41, Issue 4, 2005, Pages 565-566

  Munoz Price, L Silvia ^a,d   Lolans, Karen ^b   Quinn, John P ^b,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; CIPROFLOXACIN; DAPTOMYCIN; LINEZOLID;

ADULT; ANTIBIOTIC RESISTANCE; BACTEREMIA; CASE REPORT; DESENSITIZATION; DRUG MEGADOSE; ENTEROCOCCUS FAECALIS; FEMALE; HEMODIALYSIS; HUMAN; HYPOTENSION; LETTER; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN ALLERGY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MIDDLE AGED; VANCOMYCIN RESISTANCE;

EID: 23244446130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432121     Document Type: Letter

References (10)

1. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
2. Sader HS, Streit JM, Pritsche TR, Jones RN. Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004; 50:201-4.
3. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003; 47: 1689-93.
4. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51: 639-49.
5. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000; 44:3447-50.
6. Matushek MG, Bonten MJM, Hayden MK. Rapid preparation of bacterial DNA for pulsed-field gel electrophoresis. J Clin Microbiol 1996; 34:2598-600.
7. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. 6th ed., Vol. 23. Wayne, PA: NCCLS, 2003.
8. NCCLS. Fourteenth informational supplement: NCCLS document M100-S14. Villanova, PA: NCCLS, 2004.
9. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003;51S:iii23-30.
10. Silverman JA, Oliver N, Andrew T, Tongchuan L. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-802.